Injected subcutaneously, a peptide can yield a bioavailability of up to 50%, which is worlds above the sub-1% you might get from an orally ingested alternative.18 19 The reason for such a large disparity is that orally ingested peptides must pass through your digestive tract, where they can easily degrade, and peptide molecules are often too large to pass easily through your intestinal lining.19 Its true there are oral peptides that leverage absorption-enhancing technologies, but even with them youre getting maybe just a bit closer to 2% bioavailability little improvement over non-enhanced forms.20 Its also true that orobuccal administration (through the linings of the mouth) provides a much more bioavailable route than ingestion, but even through that route the relative absorption is less than half that of subcutaneous injection.37 Things being as they are, if you want to get the most out of your peptide therapy for weight loss, subcutaneous injection is the way to go at least until the technology improves enough to raise oral alternatives to the same level of absorptiveness
Watanabe Y, Kawai K, Ohashi S, Yokota C, Suzuki S, Yamashita K
For INS-1 832/3, Silencer Select siRNA (Thermo Fisher Scientific) targeting rat Arrb1 (ID: 129662) and Arrb2 (ID: 129665), or negative control siRNA, were used
"The health of your hair is a reflection of your internal environment
The potential mechanism of GLPs action in IBD may include promotion of tissue repair of injured epithelium, regulation of T cell differentiation and functions, regulation of innate immune cells such as macrophages and dendric cells, and reduction of proinflammatory cytokines (Fig
/assets/images/provider/photos/2775905.jpeg)
